MBX Biosciences, Inc. (NYSE:MBX - Get Free Report)'s stock price gapped up before the market opened on Monday . The stock had previously closed at $10.00, but opened at $22.40. MBX Biosciences shares last traded at $22.70, with a volume of 17,633,217 shares trading hands.
Wall Street Analysts Forecast Growth
A number of research firms recently commented on MBX. Oppenheimer reissued an "outperform" rating on shares of MBX Biosciences in a research report on Monday. Mizuho began coverage on shares of MBX Biosciences in a research report on Tuesday, August 5th. They set an "outperform" rating and a $38.00 target price for the company. Finally, Citigroup reissued an "outperform" rating on shares of MBX Biosciences in a research report on Monday. Nine equities research analysts have rated the stock with a Buy rating, Based on data from MarketBeat, the company currently has an average rating of "Buy" and a consensus price target of $37.63.
Get Our Latest Research Report on MBX
MBX Biosciences Price Performance
The stock's fifty day simple moving average is $12.93 and its 200-day simple moving average is $11.05. The firm has a market cap of $662.54 million and a PE ratio of -4.41.
Institutional Inflows and Outflows
Several institutional investors have recently made changes to their positions in MBX. BNP Paribas Financial Markets purchased a new position in shares of MBX Biosciences during the fourth quarter worth $27,000. New York State Common Retirement Fund purchased a new position in shares of MBX Biosciences during the first quarter worth $32,000. Deutsche Bank AG raised its holdings in shares of MBX Biosciences by 102.0% during the first quarter. Deutsche Bank AG now owns 8,762 shares of the company's stock worth $65,000 after purchasing an additional 4,424 shares during the last quarter. Wealthedge Investment Advisors LLC purchased a new position in shares of MBX Biosciences during the first quarter worth $88,000. Finally, Virtus Investment Advisers LLC raised its holdings in shares of MBX Biosciences by 9.6% during the second quarter. Virtus Investment Advisers LLC now owns 8,772 shares of the company's stock worth $100,000 after purchasing an additional 766 shares during the last quarter.
About MBX Biosciences
(
Get Free Report)
MBX Biosciences, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision peptide therapies for the treatment of endocrine and metabolic disorders. Its lead product candidate is MBX 2109, a parathyroid hormone peptide prodrug, which is in Phase 2 clinical trial designed as a potential long-acting hormone replacement therapy for the treatment of chronic hypoparathyroidism.
Read More
Before you consider MBX Biosciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and MBX Biosciences wasn't on the list.
While MBX Biosciences currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.